3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty
NCT ID: NCT03948386
Last Updated: 2021-05-07
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
159 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-13
Study Completion Date
2019-11-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Spinal anesthesia is commonly utilized for hip replacement surgery. Different medications used for spinal anesthesia work for different lengths of time. This study will compare three different spinal anesthesia medications in patients having hip replacement surgery to see if patients are able to get out of bed and walk earlier after surgery with one medication versus the others.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty
NCT03838874
Knee Osteoarthritis
Hip Osteoarthritis
COMPLETED
PHASE2/PHASE3
Fractionated Spinal Anesthesia With Combined Isobaric and Hyperbaric Bupivacaine for Elderly Hip Fracture Patients
NCT07288996
Spinal Anesthesia in Elderly Patients
NOT_YET_RECRUITING
NA
Pain Control Following Total Hip Arthroplasty
NCT05062356
Chronic Postoperative Pain
COMPLETED
PHASE1
Spinal Anesthesia in Total Hip Arthroplasty
NCT02818894
Total Hip Arthroplasty
TERMINATED
PHASE4
Mepivacaine Vs. Bupivacaine Spinal for TKA
NCT05765682
Total Knee Replacement
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total hip replacement is often performed under spinal anesthesia, which is the standard at Thomas Jefferson University Hospital (TJUH) and Rothman Orthopedic Specialty Hospital (ROSH) for patients without contraindications. Spinal anesthesia involves injecting a numbing medicine (local anesthetic) into the cerebrospinal fluid that bathes the spinal cord through a space between two bones in the back. This causes temporary numbness of the legs and hips and allows surgery to take place without patients feeling pain during surgery. Different local anesthetics can be used for spinal anesthesia and each works for a different duration of time. Another factor that affects how spinal anesthesia medications work is the baricity of the medication, which refers to how dense it is compared to cerebrospinal fluid (CSF). Medications that are less dense than CSF are hypobaric, those with same density are isobaric, and those with greater density are hyperbaric. For clinical purposes, this really only comes into play when positioning the patient immediately after spinal placement as patient position has different effects on the dermatomal level attained depending on baricity of the local anesthetic. Bupivacaine is a long-acting local anesthetic that has been used for several decades for total hip replacement. It is available in both hyperbaric form (with dextrose added) and isobaric form (with no dextrose added). Mepivacaine is another local anesthetic that has a shorter duration of action and is also used for spinal anesthesia in total hip replacement at many centers. All three drugs are used routinely at different centers in the United States. Despite the differences in duration that have been described from pharmacokinetic studies, a randomized, controlled study comparing the three drugs in terms of important outcomes, such as the ability to walk after surgery, has not been published yet. Therefore, the investigators want to compare the three local anesthetics in a randomized, controlled fashion to see if more patients are able to walk sooner after receiving mepivacaine spinal anesthesia than either form of bupivacaine spinal anesthesia.
Patients who are eligible will be called the night prior to surgery and the study will be explained over the phone. Patients who express interest will be recruited on the day of their scheduled surgery in the short-procedure unit. Patients will be given consent forms and time to read them and ask questions.
Preoperative Management All patients without contraindications or allergies will receive oral gabapentin and acetaminophen in the short procedure unit prior to surgery per routine practice.
Intraoperative Management The targeted spinal dermatome level to achieve will be T10 (umbilicus). For isobaric drugs, patients will sit after spinal placement for 3-5 minutes to achieve this level. For hyperbaric bupivacaine, patients will be immediately placed supine and in Trendelenberg position for 3-5 minutes to achieve adequate level and confirmed with sensory pinprick testing, which will be performed every 2 minutes beginning at spinal placement time. After spinal is placed, sedation will be titrated at the discretion of the anesthesia team to achieve the American Society of Anesthesiology's definition of moderate sedation (purposeful response to verbal or tactile stimulation, spontaneous ventilation, and no airway intervention needed) using propofol. All patients will receive tranexamic acid unless contraindicated (10 mg/kg bolus), as well as multimodal analgesia with a non-steroidal anti-inflammatory drug (NSAID) and dexamethasone 4 mg IV per routine practice.
Postoperative Management
Sensory and motor assessments will take place every 30 minutes from PACU arrival time until motor strength is 5/5 in both lower extremities in hip flexion, knee extension, and toe dorsiflexion or the patient's motor function returns to baseline. The time of return of motor function will be documented. Physical therapists will visit the patient between 3 and 3.5 hours after spinal placement to assess for ability to ambulate and perform Tinnetti test, which assesses ambulation and gait and gives a score of 0 through 28 (see attached). Urinary retention will be assessed through asking the following on postoperative day 1:
1. At what time did the participant first urinate?
2. Did participant require a Foley catheter or straight catheter to drain urine from his or her bladder?
These questions will be asked along with the following about TNS (transient neurological symptoms):
1. Does the participant have any pain in his or her lower back that goes into his or her buttocks and/or down his or her thigh that was not there before surgery?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
TNS will be defined as the new onset (within 24 hours of surgery) of back pain that radiates into the buttocks, thighs, hips, or distally. Localized back pain will not be included.
Urinary retention will be defined by inability to urinate within 8 hours, a report of distended or painful bladder occurring on postoperative days 0 or 1, either by patient report or on assessment by nursing, or the use of a Foley catheter or straight catheter.
Post-discharge phone calls
The following will be asked to patients via phone calls after discharge at 24 and 48 hours after surgery if not still in the hospital (will be asked in-person otherwise):
1. Does the participant have any back pain that was not present before surgery that goes into his/her buttocks, thighs, hips, or lower leg?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
Post-discharge data collection Readmissions within 90 days will be recorded for all patients including the reason for readmission.
General Operating Procedures Patients who agree to participate will then be randomized by a computer-generated sequence to one of the three study groups. The anesthesiologist and certified registered nurse anesthetist or resident performing the spinal will be aware of group allocation and will perform spinal anesthesia according to standard operating procedures with the assigned local anesthetic. Intraoperative sedation will be with propofol or dexmedetomidine, at the discretion of the anesthesia team. Patients will remain blinded and surgeons and those performing postoperative assessments will remain blinded as well. As all study drugs are standard spinal anesthesia drugs and readily available, the anesthesia team caring for the patient will be informed of group allocation and the appropriate drug will be selected. These doses of hyperbaric and isobaric bupivacaine are considered "low dose" and are lower than those routinely used at TJUH and ROSH. However, existing evidence shows that low-dose bupivacaine for spinal anesthesia provides adequate anesthesia time for a total joint replacement. Dosing will be as follows: isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for \< 74" height and 15 mg (3 cc) for \> or = 74" height; hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for \< 74" height and 13.125 mg (1.75 cc) for \> or = 74" height; and isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for \< 74" height and 60 mg (4 cc) for \> or = 74" height. Patients with BMI of 35 or greater will also be given the higher dose of each of the 3 medications listed above.
Intraoperative variables that will be measured include: hypotension (defined as a decrease in baseline blood pressure of 20% or greater), surgeon rating of intraoperative muscle tension (0, 1, 2, or 3 where 0 is the most relaxed and 3 is the tightest), and conversion to general anesthesia.
Postoperative variables that will be measured include: ambulation at 3-3.5 hours (primary endpoint), time to ambulation, attempts needed to ambulate, episodes of orthostatic hypotension while trying to ambulate, urinary retention, opioid consumption, pain, incidence of transient neurological symptoms up to 48 hours postoperatively, discharge readiness, and length of stay.
Post-discharge phone calls
The following will be asked to patients via phone calls after discharge on postoperative days 1 and 2 after surgery if not still in the hospital (will be asked in-person otherwise):
1. Does the participant have any pain in his/her lower back that goes into his/her buttocks and/or down his/her thigh that was not there before surgery?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
Patients who are eligible will be called the night prior to surgery and the study will be explained over the phone. Patients who express interest will be recruited on the day of their scheduled surgery in the short-procedure unit. Patients will be given consent forms and time to read them and ask questions.
Preoperative Management All patients without contraindications or allergies will receive oral gabapentin and acetaminophen in the short procedure unit prior to surgery per routine practice.
Intraoperative Management The targeted spinal dermatome level to achieve will be T10 (umbilicus). For isobaric drugs, patients will sit after spinal placement for 3-5 minutes to achieve this level. For hyperbaric bupivacaine, patients will be immediately placed supine and in Trendelenberg position for 3-5 minutes to achieve adequate level and confirmed with sensory pinprick testing, which will be performed every 2 minutes beginning at spinal placement time. After spinal is placed, sedation will be titrated at the discretion of the anesthesia team to achieve the American Society of Anesthesiology's definition of moderate sedation (purposeful response to verbal or tactile stimulation, spontaneous ventilation, and no airway intervention needed) using propofol. All patients will receive tranexamic acid unless contraindicated (10 mg/kg bolus), as well as multimodal analgesia with a non-steroidal anti-inflammatory drug (NSAID) and dexamethasone 4 mg IV per routine practice.
Postoperative Management
Sensory and motor assessments will take place every 30 minutes from PACU arrival time until motor strength is 5/5 in both lower extremities in hip flexion, knee extension, and toe dorsiflexion or the patient's motor function returns to baseline. The time of return of motor function will be documented. Physical therapists will visit the patient between 3 and 3.5 hours after spinal placement to assess for ability to ambulate and perform Tinnetti test, which assesses ambulation and gait and gives a score of 0 through 28 (see attached). Urinary retention will be assessed through asking the following on postoperative day 1:
1. At what time did the participant first urinate?
2. Did participant require a Foley catheter or straight catheter to drain urine from his or her bladder?
These questions will be asked along with the following about TNS (transient neurological symptoms):
1. Does the participant have any pain in his or her lower back that goes into his or her buttocks and/or down his or her thigh that was not there before surgery?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
TNS will be defined as the new onset (within 24 hours of surgery) of back pain that radiates into the buttocks, thighs, hips, or distally. Localized back pain will not be included.
Urinary retention will be defined by inability to urinate within 8 hours, a report of distended or painful bladder occurring on postoperative days 0 or 1, either by patient report or on assessment by nursing, or the use of a Foley catheter or straight catheter.
Post-discharge phone calls
The following will be asked to patients via phone calls after discharge at 24 and 48 hours after surgery if not still in the hospital (will be asked in-person otherwise):
1. Does the participant have any back pain that was not present before surgery that goes into his/her buttocks, thighs, hips, or lower leg?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
Post-discharge data collection Readmissions within 90 days will be recorded for all patients including the reason for readmission.
General Operating Procedures Patients who agree to participate will then be randomized by a computer-generated sequence to one of the three study groups. The anesthesiologist and certified registered nurse anesthetist or resident performing the spinal will be aware of group allocation and will perform spinal anesthesia according to standard operating procedures with the assigned local anesthetic. Intraoperative sedation will be with propofol or dexmedetomidine, at the discretion of the anesthesia team. Patients will remain blinded and surgeons and those performing postoperative assessments will remain blinded as well. As all study drugs are standard spinal anesthesia drugs and readily available, the anesthesia team caring for the patient will be informed of group allocation and the appropriate drug will be selected. These doses of hyperbaric and isobaric bupivacaine are considered "low dose" and are lower than those routinely used at TJUH and ROSH. However, existing evidence shows that low-dose bupivacaine for spinal anesthesia provides adequate anesthesia time for a total joint replacement. Dosing will be as follows: isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for \< 74" height and 15 mg (3 cc) for \> or = 74" height; hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for \< 74" height and 13.125 mg (1.75 cc) for \> or = 74" height; and isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for \< 74" height and 60 mg (4 cc) for \> or = 74" height. Patients with BMI of 35 or greater will also be given the higher dose of each of the 3 medications listed above.
Intraoperative variables that will be measured include: hypotension (defined as a decrease in baseline blood pressure of 20% or greater), surgeon rating of intraoperative muscle tension (0, 1, 2, or 3 where 0 is the most relaxed and 3 is the tightest), and conversion to general anesthesia.
Postoperative variables that will be measured include: ambulation at 3-3.5 hours (primary endpoint), time to ambulation, attempts needed to ambulate, episodes of orthostatic hypotension while trying to ambulate, urinary retention, opioid consumption, pain, incidence of transient neurological symptoms up to 48 hours postoperatively, discharge readiness, and length of stay.
Post-discharge phone calls
The following will be asked to patients via phone calls after discharge on postoperative days 1 and 2 after surgery if not still in the hospital (will be asked in-person otherwise):
1. Does the participant have any pain in his/her lower back that goes into his/her buttocks and/or down his/her thigh that was not there before surgery?
2. If yes, how would the participant rate that specific pain from 0 (no pain) to 10 (worst pain imaginable).
3. How would the participant rate his/her overall pain (0 to 10 scale)?
4. How satisfied is the participant with his/her anesthesia experience (0 to 10 scale where 0 is very dissatisfied and 10 is very satisfied)?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Osteoarthritis, Hip
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Patients who agree to participate will then be randomized by a computer-generated sequence to one of the three study groups.
Dosing will be as follows: isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74" height and 15 mg (3 cc) for \> 74" height; hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74" height and 13.125 mg (1.75 cc) for \> 74" height; and isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74" height and 60 mg (4 cc) for \> 74" height.
Dosing will be as follows: isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74" height and 15 mg (3 cc) for \> 74" height; hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74" height and 13.125 mg (1.75 cc) for \> 74" height; and isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74" height and 60 mg (4 cc) for \> 74" height.
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Outcome Assessors
The anesthesiologist and certified registered nurse anesthetist or resident performing the spinal will be aware of group allocation and will perform spinal anesthesia according to standard operating procedures with the assigned local anesthetic.
Patients will remain blinded and surgeons and those performing postoperative assessments will remain blinded as well.
Patients will remain blinded and surgeons and those performing postoperative assessments will remain blinded as well.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
isobaric bupivacaine
Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74" height and 15 mg (3 cc) for \> 74" height
Group Type
ACTIVE_COMPARATOR
isobaric bupivacaine
Intervention Type
DRUG
The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
hyperbaric bupivacaine
hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74" height and 13.125 mg (1.75 cc) for \> 74" height
Group Type
ACTIVE_COMPARATOR
hyperbaric bupivacaine
Intervention Type
DRUG
TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
isobaric mepivacaine
isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74" height and 60 mg (4 cc) for \> 74" height
Group Type
ACTIVE_COMPARATOR
isobaric mepivacaine
Intervention Type
DRUG
The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
isobaric bupivacaine
The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Intervention Type
DRUG
hyperbaric bupivacaine
TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Intervention Type
DRUG
isobaric mepivacaine
The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergoing elective primary hip replacement surgery
* American Society of Anesthesiologists physical status 1-3
* American Society of Anesthesiologists physical status 1-3
Exclusion Criteria
* hip fracture
* contraindication to spinal anesthesia (refusal, coagulopathy or recent use of anticoagulant medication that prevents spinal anesthesia, local or systemic infection)
* any other reason deemed significant by attending anesthesiologist
* any patient requiring a wheelchair for ambulation or who cannot walk 25 feet with or without an assist device at time of surgery
* presence of neuropathy in posterior thighs or buttocks
* use of greater than the equivalent of morphine 25 mg IV (oxycodone 30 mg PO) daily
* any patient deemed a poor candidate for spinal anesthesia as determined by the attending anesthesiologist
* contraindication to spinal anesthesia (refusal, coagulopathy or recent use of anticoagulant medication that prevents spinal anesthesia, local or systemic infection)
* any other reason deemed significant by attending anesthesiologist
* any patient requiring a wheelchair for ambulation or who cannot walk 25 feet with or without an assist device at time of surgery
* presence of neuropathy in posterior thighs or buttocks
* use of greater than the equivalent of morphine 25 mg IV (oxycodone 30 mg PO) daily
* any patient deemed a poor candidate for spinal anesthesia as determined by the attending anesthesiologist
Minimum Eligible Age
18 Years
Maximum Eligible Age
84 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Schwenk, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rothman Orthopedic Specialty Hospital
Bensalem, Pennsylvania, United States
Site Status
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Basques BA, Toy JO, Bohl DD, Golinvaux NS, Grauer JN. General compared with spinal anesthesia for total hip arthroplasty. J Bone Joint Surg Am. 2015 Mar 18;97(6):455-61. doi: 10.2106/JBJS.N.00662.
Reference Type
BACKGROUND
Kamel HK, Iqbal MA, Mogallapu R, Maas D, Hoffmann RG. Time to ambulation after hip fracture surgery: relation to hospitalization outcomes. J Gerontol A Biol Sci Med Sci. 2003 Nov;58(11):1042-5. doi: 10.1093/gerona/58.11.m1042.
Reference Type
BACKGROUND
Oldmeadow LB, Edwards ER, Kimmel LA, Kipen E, Robertson VJ, Bailey MJ. No rest for the wounded: early ambulation after hip surgery accelerates recovery. ANZ J Surg. 2006 Jul;76(7):607-11. doi: 10.1111/j.1445-2197.2006.03786.x.
Reference Type
BACKGROUND
Mahan MC, Jildeh TR, Tenbrunsel TN, Davis JJ. Mepivacaine Spinal Anesthesia Facilitates Rapid Recovery in Total Knee Arthroplasty Compared to Bupivacaine. J Arthroplasty. 2018 Jun;33(6):1699-1704. doi: 10.1016/j.arth.2018.01.009. Epub 2018 Jan 16.
Reference Type
BACKGROUND
Uppal V, Retter S, Shanthanna H, Prabhakar C, McKeen DM. Hyperbaric Versus Isobaric Bupivacaine for Spinal Anesthesia: Systematic Review and Meta-analysis for Adult Patients Undergoing Noncesarean Delivery Surgery. Anesth Analg. 2017 Nov;125(5):1627-1637. doi: 10.1213/ANE.0000000000002254.
Reference Type
BACKGROUND
Pawlowski J, Orr K, Kim KM, Pappas AL, Sukhani R, Jellish WS. Anesthetic and recovery profiles of lidocaine versus mepivacaine for spinal anesthesia in patients undergoing outpatient orthopedic arthroscopic procedures. J Clin Anesth. 2012 Mar;24(2):109-15. doi: 10.1016/j.jclinane.2011.06.014. Epub 2012 Feb 17.
Reference Type
BACKGROUND
Pawlowski J, Sukhani R, Pappas AL, Kim KM, Lurie J, Gunnerson H, Corsino A, Frey K, Tonino P. The anesthetic and recovery profile of two doses (60 and 80 mg) of plain mepivacaine for ambulatory spinal anesthesia. Anesth Analg. 2000 Sep;91(3):580-4. doi: 10.1097/00000539-200009000-00015.
Reference Type
BACKGROUND
Liguori GA, Zayas VM, Chisholm MF. Transient neurologic symptoms after spinal anesthesia with mepivacaine and lidocaine. Anesthesiology. 1998 Mar;88(3):619-23. doi: 10.1097/00000542-199803000-00010.
Reference Type
BACKGROUND
YaDeau JT, Liguori GA, Zayas VM. The incidence of transient neurologic symptoms after spinal anesthesia with mepivacaine. Anesth Analg. 2005 Sep;101(3):661-665. doi: 10.1213/01.ane.0000167636.94707.d3.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19D.299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pain and Sensation After Regional Anesthesia - Pilot Study
NCT03623035
COMPLETED
Pericapsular Nerve Group and Lumbar Erector Spinae Plane Blocks for Geriatrics Undergoing Total Hip Arthroplasty
NCT06904703
RECRUITING
NA
Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty
NCT02658149
COMPLETED
PHASE4
The Analgesic Efficacy of the Ultrasound-Guided Femoral Articular Branch Block for Ambulatory Hip Arthroscopy
NCT03449680
COMPLETED
NA
Ropivacaine Hypobaric Spinal Anaesthesia in Traumatic Hip Surgery
NCT01005550
COMPLETED
PHASE4
Effect of Local Infiltration Anesthesia With Ropivacaine on Postoperative Pain After Hip Hemiarthroplasty
NCT02585011
COMPLETED
NA
Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
NCT02242201
COMPLETED
PHASE4
Randomized, Controlled Trial Comparing the Effectiveness of Sedation-Epidural Anesthesia to Spinal Anesthesia in Outpatient Hip or Knee Arthroplasty.
NCT06332443
RECRUITING
NA
The Pericapsular Nerve Block in Total Hip Arthroplasty
NCT04729686
RECRUITING
PHASE4
Fascia Iliaca Blocks for Pain Control After Total Hip Arthroplasty
NCT03375112
COMPLETED
PHASE4
Comparison Between Blocks or Not in Joint Arthroplasty
NCT06230081
ACTIVE_NOT_RECRUITING
NA
The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement
NCT02630160
COMPLETED
PHASE4
Efficacy of an Epidural Versus a Fascia Iliaca Compartment Catheter After Hip Surgery
NCT01835106
WITHDRAWN
NA
Motor-Sparing Peripheral Nerve Blockade Facilitates Mobility Post Total Knee Arthroplasty: A Randomized Controlled Trial
NCT02773537
COMPLETED
NA
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
NCT04690647
COMPLETED
NA
Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy
NCT02346357
UNKNOWN
NA
Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery
NCT02289937
COMPLETED
PHASE4
Hemodynamic Effect of Lumbosacral Plexus Blockade Versus Spinal Anesthesia
NCT02544269
TERMINATED
PHASE4
Regional Anesthesia in Hip Arthroscopy
NCT02674113
WITHDRAWN
NA
Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy
NCT03432650
COMPLETED
PHASE3
Ultrasound-guided Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Total Hip Arthroplasty
NCT03069183
COMPLETED
PHASE2/PHASE3
Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty
NCT06577155
RECRUITING
PHASE2
Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
NCT03977454
COMPLETED
PHASE2
Local Analgesia Versus Local Peroperative Infiltration After Total Hip Replacement
NCT02720471
COMPLETED
PHASE3
Continuous Spinal Anesthesia Versus Epidural Anesthesia in Geriatric
NCT06340256
COMPLETED
NA